Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 219

1.

A Pooled Analysis of the Phase 3 REVIVE Trials: Randomized, Double-blind Studies to EValuate the Safety and Efficacy of Iclaprim Versus Vancomycin for trEatment of Acute Bacterial Skin and Skin Structure Infections.

Huang DB, Corey GR, Holland TL, Lodise T, O'Riordan W, Wilcox MH, File TM Jr, Dryden M, Balser B, Desplats E, Torres A.

Int J Antimicrob Agents. 2018 May 18. pii: S0924-8579(18)30143-2. doi: 10.1016/j.ijantimicag.2018.05.012. [Epub ahead of print]

PMID:
29783024
2.

A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1.

Huang DB, O'Riordan W, Overcash JS, Heller B, Amin F, File TM, Wilcox MH, Torres A, Dryden M, Holland TL, McLeroth P, Shukla R, Corey GR.

Clin Infect Dis. 2018 Apr 3;66(8):1222-1229. doi: 10.1093/cid/cix987.

PMID:
29281036
3.

The effect of pulmonary surfactant on the in vitro activity of Iclaprim against common respiratory bacterial pathogens.

Huang DB, Duncan LR, Flamm RK, Dryden M, Corey GR, Wilcox MH, Torres A, File TM Jr.

Diagn Microbiol Infect Dis. 2018 Jan;90(1):64-66. doi: 10.1016/j.diagmicrobio.2017.09.011. Epub 2017 Sep 20.

PMID:
29103875
4.

A Phase II Randomized, Double-blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-positive Pathogens.

Huang DB, File TM Jr, Torres A, Shorr AF, Wilcox MH, Hadvary P, Dryden M, Corey GR.

Clin Ther. 2017 Aug;39(8):1706-1718. doi: 10.1016/j.clinthera.2017.07.007. Epub 2017 Jul 27.

PMID:
28756068
5.

Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.

File TM Jr, Eckburg PB, Talbot GH, Llorens L, Friedland HD.

Int J Antimicrob Agents. 2017 Aug;50(2):247-251. doi: 10.1016/j.ijantimicag.2017.01.043. Epub 2017 Jun 6.

PMID:
28599867
6.

Reply to Bush and Kaye.

Kullar R, Goff DA, Bauer KA, File TM Jr.

Clin Infect Dis. 2017 Oct 16;65(9):1596. doi: 10.1093/cid/cix531. No abstract available.

PMID:
28591832
7.

Eight Habits of Highly Effective Antimicrobial Stewardship Programs to Meet the Joint Commission Standards for Hospitals.

Goff DA, Kullar R, Bauer KA, File TM Jr.

Clin Infect Dis. 2017 Apr 15;64(8):1134-1139. doi: 10.1093/cid/cix065. Review.

PMID:
28203781
8.

Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study.

Llop CJ, Tuttle E, Tillotson GS, LaPlante K, File TM Jr.

Hosp Pract (1995). 2017 Feb;45(1):1-8. doi: 10.1080/21548331.2017.1279012. Epub 2017 Jan 18.

PMID:
28064542
9.

Nosocomial (Health Care-Associated) Legionnaire's Disease.

Agarwal S, Abell V, File TM Jr.

Infect Dis Clin North Am. 2017 Mar;31(1):155-165. doi: 10.1016/j.idc.2016.10.011. Epub 2016 Dec 12. Review.

PMID:
27979683
10.

Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, CarratalĂ  J, El Solh AA, Ewig S, Fey PD, File TM Jr, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL.

Clin Infect Dis. 2016 Sep 1;63(5):575-82. doi: 10.1093/cid/ciw504.

11.

SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.

File TM Jr, Rewerska B, Vucinic-Mihailovic V, Gonong JRV, Das AF, Keedy K, Taylor D, Sheets A, Fernandes P, Oldach D, Jamieson BD.

Clin Infect Dis. 2016 Oct 15;63(8):1007-1016. doi: 10.1093/cid/ciw490. Epub 2016 Jul 22.

PMID:
27448679
12.

Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, CarratalĂ  J, El Solh AA, Ewig S, Fey PD, File TM Jr, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL.

Clin Infect Dis. 2016 Sep 1;63(5):e61-e111. doi: 10.1093/cid/ciw353. Epub 2016 Jul 14.

13.

Bacterial Pneumonia in Older Adults.

Marrie TJ, File TM Jr.

Clin Geriatr Med. 2016 Aug;32(3):459-77. doi: 10.1016/j.cger.2016.02.012. Epub 2016 Apr 20. Review.

PMID:
27394017
14.

The Evolving Role of Antimicrobial Stewardship in Management of Multidrug Resistant Infections.

Goff DA, File TM Jr.

Infect Dis Clin North Am. 2016 Jun;30(2):539-551. doi: 10.1016/j.idc.2016.02.012. Review.

PMID:
27208772
15.

Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010-2011.

Fleming-Dutra KE, Hersh AL, Shapiro DJ, Bartoces M, Enns EA, File TM Jr, Finkelstein JA, Gerber JS, Hyun DY, Linder JA, Lynfield R, Margolis DJ, May LS, Merenstein D, Metlay JP, Newland JG, Piccirillo JF, Roberts RM, Sanchez GV, Suda KJ, Thomas A, Woo TM, Zetts RM, Hicks LA.

JAMA. 2016 May 3;315(17):1864-73. doi: 10.1001/jama.2016.4151.

PMID:
27139059
16.

Approaches to Modifying the Behavior of Clinicians Who Are Noncompliant With Antimicrobial Stewardship Program Guidelines.

Goldstein EJ, Goff DA, Reeve W, Naumovski S, Epson E, Zenilman J, Kaye KS, File TM Jr.

Clin Infect Dis. 2016 Aug 15;63(4):532-8. doi: 10.1093/cid/ciw247. Epub 2016 Apr 20.

PMID:
27098167
17.

Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials.

Taboada M, Melnick D, Iaconis JP, Sun F, Zhong NS, File TM, Llorens L, Friedland HD, Wilson D.

J Antimicrob Chemother. 2016 Jun;71(6):1748-9. doi: 10.1093/jac/dkw136. Epub 2016 Apr 13. No abstract available.

PMID:
27076104
18.

Diagnosis and Treatment of Clostridium difficile Infection (CDI).

Gerding DN, File TM Jr, McDonald LC.

Infect Dis Clin Pract (Baltim Md). 2016 Jan;24(1):3-10. doi: 10.1097/IPC.0000000000000350.

19.

Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials.

Taboada M, Melnick D, Iaconis JP, Sun F, Zhong NS, File TM, Llorens L, Friedland HD, Wilson D.

J Antimicrob Chemother. 2016 Apr;71(4):862-70. doi: 10.1093/jac/dkv415. Epub 2015 Dec 24. Review. Erratum in: J Antimicrob Chemother. 2016 Jun;71(6):1748-9.

PMID:
26702925
20.

Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trials.

Lodise TP, Anzueto AR, Weber DJ, Shorr AF, Yang M, Smith A, Zhao Q, Huang X, File TM.

Antimicrob Agents Chemother. 2015 Feb;59(2):1119-26. doi: 10.1128/AAC.03643-14. Epub 2014 Dec 8.

Supplemental Content

Loading ...
Support Center